VERAXA Biotech AG (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG. The company will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. This milestone marks a significant step for the company as it advances its pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue.
The business combination is expected to provide VERAXA with the capital and public market presence needed to accelerate its drug development programs. According to the company, proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate, indicating potential for this novel approach in oncology.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
Voyager Acquisition Corp., the special purpose acquisition company that merged with VERAXA, has a mission to revolutionize the healthcare sector through mergers, stock purchases, or business combinations. Its team of experienced executives includes expertise in investing, operations, and medical innovation, supported by a vast network of connections. With these strengths, Voyager seeks to drive success and scale companies to unprecedented heights in the healthcare industry.
The completion of this business combination and the start of trading on Nasdaq represent a critical juncture for VERAXA. The company now has access to public capital markets, which can facilitate further research and development of its BiTAC platform. For investors and the biotech industry, this development highlights the growing interest in bispecific antibodies and antibody-drug conjugates as targeted cancer therapies. The potential impact of VERAXA's technology lies in its ability to selectively target cancer cells while minimizing damage to healthy tissue, which could lead to more effective treatments with fewer side effects.
As VERAXA progresses toward clinical development, the data from its preclinical studies will be closely watched by the medical community. If successful, the BiTAC platform could offer new therapeutic options for patients with various cancers. The company's focus on quality-by-design principles and its foundation in European Molecular Biology Laboratory research underscore its commitment to scientific rigor.
For more information, visit the company's newsroom at http://ibn.fm/VRXA.
